CLDX FY 2012 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+20.9% YoY

Gross Profit

$427,0003.8% margin

Operating Income

-$58M-518.5% margin

Net Income

-$59M-527.8% margin

EPS (Diluted)

$-15.37

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$126M

Total Liabilities

$30M

Stockholders' Equity

$96M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$9M	+20.9%
Gross Profit	$427,000	$146,000	+192.5%
Operating Income	-$58M	-$43M	-33.8%
Net Income	-$59M	-$45M	-32.0%